Baudax Bio Inc. (BXRX)
0.02
-0.00 (-1.48%)
At close: Feb 29, 2024, 8:53 PM
Company Description
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings.
The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics.
Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine.
The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Baudax Bio Inc.
| Country | United States |
| IPO Date | Nov 14, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Geraldine A. Henwood Ph.D. |
Contact Details
Address: 490 Lapp Road Malvern, Pennsylvania United States | |
| Website | https://www.baudaxbio.com |
Stock Details
| Ticker Symbol | BXRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001780097 |
| CUSIP Number | 07160F206 |
| ISIN Number | US07160F4046 |
| Employer ID | 47-4639500 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Dr. Geraldine A. Henwood Ph.D. | President, Chief Executive Officer & Director |
| Dr. Chan Kim Yong Ph.D. | Chief Scientific Officer & Director |
| Mike Choi | Vice President of Financial Planning & Analysis |
| Natalie McAndrew | Consultant & Principle Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 28, 2024 | 8-K | Current Report |
| Feb 15, 2024 | 25-NSE | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Dec 13, 2023 | 8-K | Current Report |
| Nov 22, 2023 | 424B3 | Filing |
| Nov 20, 2023 | 10-Q | Quarterly Report |
| Nov 15, 2023 | NT 10-Q | Filing |
| Nov 15, 2023 | 8-K | Current Report |
| Oct 25, 2023 | 8-K | Current Report |